February 12, 2008 - Boston Scientific Corp. reported that a U.S. District Court jury in Marshall, TX, has reached a verdict in favor of Bruce Saffran, M.D., over a patent infringement on drug-eluting stents, a decision which Boston Scientific plans to appeal.
The jury found that the Company's TAXUS Express and TAXUS Liberte drug-eluting stent products infringe Dr. Saffran's patent and that the patent is valid. No injunction was requested, but the jury awarded damages of $431 million.
The Boston Scientific believes the jury verdict is unsupported by both the evidence and the law. On these grounds, Boston Scientific plans to seek to overturn the verdict in post-trial motions before the District Court and, if unsuccessful, to appeal to the U.S. Court of Appeals for the Federal Circuit. The company believes it will prevail on appeal.
For more information: www.bostonscientific.com.